⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 13, 2024JAMA

New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19

View at Publisher

Ask AI

Bookmark

Share

Abstract

This Medical News story discusses new guidelines for the use of pemivibart, a monoclonal antibody marketed as Pemgarda, as preexposure prophylaxis against COVID-19 in immunocompromised individuals.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Anna Bock (2024) studied this question.

synapsesocial.com/papers/68e58930b6db643587525453 https://doi.org/10.1001/jama.2024.18589

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis2024 · 8 citations
2Real-world outcomes following pemivibart for COVID-19 pre-exposure prophylaxis in immunocompromised patients with hematologic malignancies2025
3660. Early Experience with Use of Pemivibart for the Pre-exposure Prophylaxis of Coronavirus Disease 2019Cohort Study · 2026
4Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages2024 · 10 citations
5Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised RemainsMeta-Analysis · 2026

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised Remains2025
2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness2025
Organoid-based evaluation of SA55 and Pemivibart against evolving SARS-CoV-2 variants2026
Left Bundle-Branch Area Pacing vs Right Ventricular Pacing for Atrioventricular Block and Preserved Left Ventricular FunctionJAMA · 2026
JamaJAMA · 2026